Downgrade Alert for MAP Pharmaceuticals (MAPP)
MAP Pharmaceuticals (NASDAQ:MAPP) was downgraded from Buy to Hold at Deutsche Bank today. The stock closed yesterday at $24.75 on volume of 1.2 million shares, below average daily volume of 1.9 million.
MAP Pharmaceuticals share prices have moved between a 52-week high of $24.78 and a 52-week low of $10.54 and closed yesterday at 135% above that low price at $24.75 per share. In the last five trading sessions, the 50-day moving average (MA) has climbed 4.5% while the 200-day MA has risen 1.2%.
MAP Pharmaceuticals Inc. is a biopharmaceutical company. The Company develops treatments for respiratory and CNS diseases.
MAP Pharmaceuticals (NASDAQ:MAPP) is currently priced 0.0% above its average consensus analyst price target of $24.75. The stock should discover initial support at its 50-day moving average (MA) of $15.79 and subsequent support at its 200-day MA of $14.38.
SmarTrend recommended that subscribers consider buying shares of MAP Pharmaceuticals on November 23rd, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $15.11. Since that recommendation, shares of MAP Pharmaceuticals have risen 63.9%. We continue to monitor MAPP for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: analyst upgrades/downgrades map pharmaceuticals